Literature DB >> 19232321

Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2.

Qin Chen1, Li Dong, Lian Wang, Lina Kang, Biao Xu.   

Abstract

Endothelial progenitor cells (EPCs) exhibit impaired function in the context of diabetes, and advanced glycation end products (AGEs), which accumulate in diabetes, may contribute to this. In the present study, we investigated the mechanism by which AGEs impair late EPC function. EPCs from human umbilical cord blood were isolated, and incubated with AGE-modified albumin (AGE-albumin) at different concentrations found physiologically in plasma. Apoptosis, migration, and tube formation assays were used to evaluate EPC function including capacity for vasculogenesis, and expression of the receptor for AGEs (RAGE), Akt, endothelial nitric oxide synthase (eNOS), and cycloxygenase-2 (COX-2) were determined. Anti-RAGE antibody was used to block RAGE function. AGE-albumin concentration-dependently enhanced apoptosis and depressed migration and tube formation, but did not affect proliferation, of late EPCs. High AGE-albumin increased RAGE mRNA and protein expression, and decreased Akt and COX-2 protein expression, whilst having no effect on eNOS mRNA or protein in these cells. These effects were inhibited by co-incubation with anti-RAGE antibody. These results suggest that RAGE mediates the AGE-induced impairment of late EPC function, through down-regulation of Akt and COX-2 in these cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232321     DOI: 10.1016/j.bbrc.2009.02.040

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

Review 1.  The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Circ Res       Date:  2010-03-19       Impact factor: 17.367

Review 2.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

3.  Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.

Authors:  Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

Review 4.  The promise of cell-based therapies for diabetic complications: challenges and solutions.

Authors:  Yagna P R Jarajapu; Maria B Grant
Journal:  Circ Res       Date:  2010-03-19       Impact factor: 17.367

5.  Soluble Receptor for Advanced Glycation End Products Improves Stromal Cell-Derived Factor-1 Activity in Model Diabetic Environments.

Authors:  Melissa Przyborowski Olekson; Renea A Faulknor; Henry C Hsia; Ann Marie Schmidt; François Berthiaume
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-12-01       Impact factor: 4.730

Review 6.  Endothelial Progenitor Cells Biology in Diabetes Mellitus and Peripheral Arterial Disease and their Therapeutic Potential.

Authors:  Anna Pyšná; Robert Bém; Andrea Němcová; Vladimíra Fejfarová; Alexandra Jirkovská; Jitka Hazdrová; Edward B Jude; Michal Dubský
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

Review 7.  RAGE and the pathogenesis of chronic kidney disease.

Authors:  Vivette D'Agati; Ann Marie Schmidt
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

8.  Differential gene expression in Lin-/VEGF-R2+ bone marrow-derived endothelial progenitor cells isolated from diabetic mice.

Authors:  Daniel Barthelmes; Ling Zhu; Weiyong Shen; Mark C Gillies; Mohammad R Irhimeh
Journal:  Cardiovasc Diabetol       Date:  2014-02-12       Impact factor: 9.951

9.  Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation.

Authors:  M L Balestrieri; L Servillo; A Esposito; N D'Onofrio; A Giovane; R Casale; M Barbieri; P Paolisso; M R Rizzo; G Paolisso; R Marfella
Journal:  Diabetologia       Date:  2012-10-16       Impact factor: 10.122

10.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.